Epic Tools for Epic Science

As Bio-Techne, we have united multiple brands to provide a unique and comprehensive product portfolio. Together, our brands provide world class products and services for life-science research and clinical applications.

Investor Presentation

Latest Presentation

September 15, 2016

2016 Investor Day Presentation

View Presentation View All

Current

Reportable Segments

  • Biotechnology R&D Systems®, PrimeGene®, Novus Biologicals®, Tocris®
  • Diagnostics R&D Systems®, Cliniqa®, Bionostics®, BiosPacific®
  • Protein Platforms ProteinSimple®, Simple Plex™, Milo™

Revenue

Customer Segmentation

  • Pharma/Biotechnology
  • Academia
  • OEM
  • Distributors

Revenue

Geography

  • Americas
  • EMEA
  • APAC

$144 million

Third Quarter Net Sales

$94 Million

Third Quarter Gross Margin

$21 Million

Third Quarter Net Income

Sign up for E-Mail Alerts

Sign up today

Latest Annual Report

2016 Annual Report

$499M

Fiscal 2016 Net Sales

$150M

Fiscal 2016 Operating Income

$144M

Fiscal 2016 Cash Flow From Operations

View Annual Report Get Alerts

Stock Information

Bio-Techne Corporation

NASDAQ: TECH

 |  View Detailed Stock Info

Price
Change
Volume
Day Range
52 Week Range

Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins - notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds - which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.

The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,650 employees worldwide.

Fast Facts

Net sales (July 2015 to June 2016)

$499 million

Employees Worldwide

1,650+

Products

500,000+

Journal citations

330,000+

Incorporated in Minnevapolis, Minnesota

1981

Leadership

Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is a source of our success.

IR Contact Information

Company Information

Corporate Secretary
614 McKinley Place NE
Minneapolis, MN 55413

Investor Relations

David Clair
T: 646-277-1266
ir@bio-techne.com

Transfer Agent

American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
help@astfinancial.com